Article
A qualitative study of unaffected ATM and CHEK2 carriers: How participants make meaning of 'moderate risk' genetic results in a population breast cancer screening trial.
Journal of genetic counseling - 1 Dec 2022
James Jennifer Elyse, Riddle Leslie, Caruncho Mikaella, Koenig Barbara Ann, Joseph Galen
Abstract excerpt
Relatively little is known about experiences of individuals with a pathogenic variant in a moderately penetrant breast cancer gene, particularly those without a personal history of cancer. The WISDOM trial is testing a model of risk-based breast cancer screening that integrates genomic (nine genes and polygenic risk) and other risk factors. In the context of an embedded Ethical, Legal, and Social Implications...
Topics
- Female
- Humans
- Ataxia Telangiectasia Mutated Proteins
- Breast Neoplasms
- Checkpoint Kinase 2
- Early Detection of Cancer
- Genetic Predisposition to Disease
- Genetic Testing
- Risk Factors